- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | LIXTE joins Russell Microcap Index | 1 | Seeking Alpha | ||
| Fr | LIXTE added to Russell Microcap Index effective today | 1 | Investing.com | ||
| Fr | Lixte Biotechnology Holdings, Inc.: LIXTE Joins Russell Microcap Index | 1 | GlobeNewswire (USA) | ||
| 18.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.06. | LIXTE to loan $6.5M to NOMAD ahead of acquisition close | 2 | Investing.com | ||
| 18.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 | 921 | GlobeNewswire (Europe) | Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs - Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA... ► Artikel lesen | |
| 12.06. | LIXTE Biotechnology sings deal to acquire 100% of NOMAD to meet grid demand | 2 | Seeking Alpha | ||
| 12.06. | Lixte Biotechnology to acquire NOMAD Power Systems | 1 | Investing.com | ||
| 12.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS) | 217 | GlobeNewswire (Europe) | Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity BOCA RATON, Fla. & WATERBURY... ► Artikel lesen | |
| 03.06. | LIXTE Biotechnology prices $16.6M registered direct offering | 1 | Seeking Alpha | ||
| 03.06. | Lixte Biotechnology raises $16.6 million in direct offering | 2 | Investing.com | ||
| 03.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth | 1 | GlobeNewswire (USA) | ||
| 01.06. | Lixte Biotechnology Shares Slip 6% Despite Pivot To AI Energy Infrastructure Business | 1 | RTTNews | ||
| 01.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors | 147 | GlobeNewswire (Europe) | Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure... ► Artikel lesen | |
| 14.05. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update | 193 | GlobeNewswire (Europe) | BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen | |
| 14.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 17.04. | Lixte Biotechnology stellt Vergütung für Management um: RSUs ersetzen Aktienoptionen | 5 | Investing.com Deutsch | ||
| 17.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year | 626 | GlobeNewswire (Europe) | BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| EVOTEC | 4,906 | +1,41 % | Evotec-Aktie mit -91% - ist das die letzte Chance? | Die Evotec-Aktie hat seit ihrem Allzeithoch rund -91% an Wert verloren und zählt damit zu den größten Verlierern der vergangenen Jahre. Nach dem massiven Abverkauf bewegt sich der Kurs nun in einer... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,750 | -2,97 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,200 | -1,97 % | Immatics N.V. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MANNKIND | 3,577 | 0,00 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,520 | 0,00 % | Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note | ||
| MARINOMED BIOTECH | 8,800 | -5,88 % | HV-Kalender: ams Osram, Eurokai, Evotec, Exasol, Formycon, Jenoptik, Marinomed, Masterflex, OHB, Renk | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| IMMUNIC | 13,115 | -1,83 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.